Abstract
Introduction
Raloxifene, a selective estrogen receptor modulator (SERM), has been well recognized to be an efficient therapeutic agent for postmenopausal osteoporosis (1) . Raloxifene reportedly increases the vertebra and femoral neck bone mineral density, and reduces the risk of vertebral fracture (1) . In addition, raloxifene has been reported to significantly reduce the incidence of breast cancer (1) . Raloxifene is thought to be a preferable medicine for postmenopausal women. However, the use of this drug as well as estrogen is associated with an increased risk of developing venous thromboembolus (2) . Platelet aggregation and the coagulation system are important for the formation of the thrombus. Although significant attention has been paid to the coagulation system, the influence of raloxifene on platelet aggregation is not known.
Platelet aggregation is usually measured using either the optical density (OD) method (3) or the impedance method (4) (6) . Recently, an important role of platelet microaggregation in the circulation and a significant alteration of platelet microaggregation in pathogenesis were reported by the creation of a laser LS system for microaggregates (7) (8) (9) . Therefore, an LS system was employed for the detection of microaggregates of platelets in our clinical study (10) .
Adenosine diphosphate (ADP) is considered to be a weak physiological agonist for platelet aggregation by itself in comparison, for example, to thrombin or collagen (11) . However, ADP is a necessary cofactor for normal activation T a b l e 1 . Cl i n i c a l F e a t u r e of platelets by other agonists. Even if it is weak agonist for platelet aggregation, low-concentration ADP amplifies the effects (12) . A recent investigation revealed that purinoreceptor P2Y12 is a principal receptor for mediating ADPinduced platelet aggregation and the thromboenbolism (13, 14) . (Fig. 3) .
It is well known that a lack of α2-antiplasmin (α2AP), a major component of fibrinolytic system, causes an excess of plasmin, and that plasmin plays an important role in the formation of platelet aggregates. Consequently, the reduction of α2AP could be a risk factor for the activation of platelets resulting in thrombus formation (9) . The α2AP activity was examined in this case to determine the effect of raloxifene treatment on the fibrinolytic system. The α2AP activity gradually increased from the beginning of raloxifenetreatment, and it was sustained up to 4 weeks after the cessation of the medication (Fig. 4) .
Discussion

This report presents a case of primary osteoporosis showing platelet hyper-aggregability to ADP, closely related to the administration of the standard dose of raloxifene. This is probably the first report clearly showing raloxifene-induced unusual platelet aggregation, which was detectable using the LS method. Interestingly, the hyper-sensitivity was correlated with the enhancement of Akt phosphorylation induced by ADP in platelets. The platelets play an important role in normal homeostasis and abnormal activation of platelets thus leading to thrombosis. During vascular injury or conditions of high shear, exposure of the collagen-rich subendothelium
T a b l e 2 . L a b o r a t o r y Da t a activates the platelets and results in the formation of a stable thrombus due to the combined action of ADP secreted from platelet-dense granules and generated thrombin (14, 17). The present results suggest that raloxifene could induce hyperreactivity of platelet aggregation by increased sensitivity to ADP stimulation and by Akt activation. The hypersensitivity of platelets shown here might lead us to pay attention to the risk of arterial thrombosis, in addition to the increased hazard ratio of venous thromboembolism, under standard raloxifene treatment for osteoporosis.
Prior studies have shown that PI3K is a necessary component which plays a pivotal role in the signaling of purinoreceptor P2Y12 in platelets (14, 18) d i c a t e s s ma l l a g g r e g a t e s ; g r e e n l i n e , me d i u m a g g r e g a t e s ; r e d  l i n e , l a r g e a g g r e g a t e s ; a n d b l a c k l i n e , o p t i c a l d e n s i t y ( %T ) .  P RP s a mp l e s we r e o b t a i n e d b e f o r e ( A) , a f t e r 2 we e k s ( B ) a n d  a f t e r 4 we e k s ( C) o f r a l o x i f e n e a d mi n i s t r a t i o n , a n d t h e ADP  ( 1 μ M) -i n d u c e d p l a t e l e t a g g r e g a t i o n wa s d e t e r mi n e d u s i n g a  P A-2 0 0 a g g r e g o me t e r . (13, 20 In conclusion, a standard dosage of raloxifene, one type
. A potential downstream effector for PI3K is Akt, which contributes to fibrinogen receptor activation and platelet aggregation. In addition, PI3K/ Akt signaling is also reportedly involved in the release of ADP-containing granules (18). The platelet-aggregated form consists of two types of platelet membrane receptors, glycoprotein (GP) IIb/IIIa and GPIb/V/IX. GPIIb/IIIa not only binds fibrinogen and von Willebrand factor (vWF) to mediate platelet aggregation and adhesion, but it also serves as a signaling receptor. ADP induces the signaling, which activates the receptor function of GPIIb/IIIa for soluble fibrinogen, and ADP-induced platelet aggregation promotes the
F i g u r e 1 . T h e c h a n g e i n E D5 0 f o r ADP -i n d u c e d p l a t e l e t a g g r e g a t i o n . P RP s a mp l e s we r e o b t a i n e d d u r i n g t h e t r e a t me n t a n d 4 we e k s a f t e r t h e c e s s a t i o n o f r a l o x i f e n e a d mi n i s t r a t i o n . P RP wa s c h r o n o l o g i c a l l y o b t a i n e d f r o m f r e s h l y d r a wn v e n o u s b l o o d s a mp l e s . T h e E D5 0 f o r ADP wa s d e t e r mi n e d .
F i g u r e 2 . P l a t e l e t a g g r e g a b i l i t y a f t e r t h e a d d i t i o n o f ADP me a s u r e d wi t h t h e l a s e r -l i g h t s c a t t e r i n g me t h o d . B l u e l i n e i n -
binding of fibrinogen to GPIIb/IIIa (19). The P2Y12 receptor is involved in the constitution of stable macroaggregates (irreversible change) through full activation of the GPIIb/IIIa
F i g u r e 3 . T h e c h a n g e i n ADP -i n d u c e d p l a t e l e t a g g r e g a t i o n a n d t h e p h o s p h o r y l a t i o n o f Ak t i n t h e p l a t e l e t s u n d e r t h e t r e a t me n t o f r a l o x i f e n e . Un d e r t h e t r e a t me n t o f r a l o x i f e n e a n d 4 we e k s a f t e r t h e c e s s a t i o n , P RP s a mp l e we r e o b t a i n e d a t t h e i n d i c a t e d t i me . T h e p l a t e l e t a g g r e g a t i o n ( %) i n d u c e d b y ADP ( 1 μ M) wa s d e t e r mi n e d u s i n g a P A-2 0 0 a g g r e g o me t e r , a n d t h e n wi t h t h e s a me s a mp l e s , t h e p h o s p h o r y l a t i o n o f Ak t i n d u c e d b y ADP ( 1 μ M) wa s e x a mi n e d a t 2 4 we e k s a n d 4 we e k s a f t e r t h e c e s s a t i o n o f t h e t r e a t me n t . T h e p l a t e l e t e x t r a c t s we r e s e p a r a t e d b y S DS -P AGE a n d a We s t e r n b l o t a n a l y s i s wa s p e r f o r me d wi t h a n t i b o d i e s a g a i n s t e i t h e r p h o s p h o -s p e c i f i c Ak t o r Ak t .
F i g u r e 4 . T h e c h a n g e i n t h e α 2 -a n t i p l a s mi n ( α 2 AP ) a c t i v i t y . Un d e r t h e t r e a t me n t o f r a l o x i f e n e a n d 4 we e k s a f t e r t h e c e s s a t i o n , P RP s a mp l e s we r e o b t a i n e d a t t h e i n d 
